
Peter Lebowitz/LinkedIn
Jun 11, 2025, 13:02
Peter Lebowitz: True Innovation – A Novel and Ideal Target for a Solid Tumor TCE
“While it took some time to get to the right approach with KLK2, these results make the effort well worth it. True innovation. A novel and ideal target for a solid tumor TCE with a therapeutic index that breaks new ground. Congratulations to the brave trailblazers on the J&J prostate cancer team. Huge kudos to Chuck Drake as the champion of this target. Looking forward to seeing the combo data!!“
More posts featuring Prostate Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 11, 2025, 13:02